Retatrutides glucagon receptor activity is one of the features that makes it different from tirzepatide and semaglutide
Collagen-based scaffolds exhibit high porosity and low modulus, which supports vascular ingrowth and enhances volume retention
CKD alters how the body processes drugs, making standard doses potentially unsafe
Retatrutide : Single-molecule triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously
Patent protection : GLP-1 medications are still under patent, which means there are no low-cost generic versions yet, and are only sold by the brand-name pharmaceutical company that manufactures them
Some people report burning, tingling or increased skin sensitivity, Kratovil says